期刊文献+

血小板活化因子水解酶与原发性肾病综合征的相关性 被引量:1

Correlation between Platelet Activating Factor Acetylhydrolase and Primary Nephrotic Syndrome
暂未订购
导出
摘要 目的探讨血小板活化因子水解酶(PAF-AH)活性与原发性肾病综合征(PNS)相关性。方法将78例患儿分为激素敏感、激素依赖和激素耐药组,经激素规律治疗6个月后用分光光度计检测血浆PAF-AH活性及总胆固醇值。结果PAF-AH活性与血总胆固醇值呈正相关,但3组病例之间胆固醇值无显著差异,3组患儿两两相比有显著性差异;除激素敏感组外,另2组与正常对照有显著差异。结论PAF-AH与患儿激素治疗敏感性有一定相关性,激素耐药组PAF-AH活性高于激素依赖组,这是否与PAF-AH基因突变有关。 Objective To investigate the association of platelet activating factor acetylhydrolase(PAF- AH) activity in children with primary nephrotic syndrome(PNS). Methods The plasma PAF AH activity was measured in 78 children with PNS who were divided into 3 groups: steroid responsive nephritic, steroid dependent nephritic, steroid - resistent nephritic, after they had been given steroid for 6 months. The plasma PAF- AH activity were also measured in 60 healthy children at the same age, with spectrophotometric assay, at the ame time, the blood cholesterol was measured. Results The blood cholesterol has positive correlation with the plasma PAF AH activity, there was no significant difference of the blood cholesterol among 3 groups in nephrotic syndrome children, there was a significant difference in the plasma PAF - All activity among 3 groups in PNS children, but there was no significant difference in the plasma PAF- AH activity between the groups of steroid responsive nephritic and healthy children. Conclusion Plasma PAF AH activity is related to the sensibility to steroid treatment in children's PNS, and the plasma PAF- AH activity in steroid - resistent nephritic is higher than steroid- dependent nephritic. It is a question that if gene mutation is related with PAF AH activity.
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2006年第17期1145-1146,共2页 Journal of Applied Clinical Pediatrics
基金 广西自然科学基金项目资助(桂科自0339043)
关键词 肾病综合征 原发性 1-烷基-2-乙酰甘油磷酸胆碱脂酶 儿童 nephrotic syndrome, primary 1-alkyl-2-acetylylycerophosphocholine exterase child
  • 相关文献

参考文献12

  • 1Castro Faria Neto HC,Stafforini DM,Prescott SM,et al.Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase[J].Mem Inst Oswaldo Cruz,2005,100(suppl 1):S83-S91.
  • 2Balafa OC,Kirabina SAP,Pappas CA,et al.Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins[J].Nephron Physio1,2004,97(3):45-52.
  • 3中华医学会儿科学分会肾脏病学组,姚勇,杨霁云,陈述枚,丁洁.小儿肾小球疾病的临床分类、诊断及治疗[J].中华儿科杂志,2001,39(12):746-749. 被引量:1542
  • 4Lee E,Lee SJ,Lee TY,et al.cDNA cloning and expression of biologically active platelet activating factor-acetylhydrolase (PAF-AH)from bovine mammary gland[J].Biol Pharm Bull,2005,28 (4):580-583.
  • 5Arakawa H,Qian JY,Baatar D,et al.Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation,shear stress-induced thrombosis,and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits[J].Circulation,2005,111 (24):3302-3309.
  • 6Iso ON,Noto H,Hara M,et al.Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis[J].Mol Ther,2006,13(1):118-126.
  • 7Stafforini DM,Sheller JR,Blackwell TS,et al.Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases[J].J Biol Chem,2006,281(8):4616-4623.
  • 8Androulakis N,Durand H,Ninio E,et al.Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation[J].J Lipid Res,2005,46 (9):1923-1932.
  • 9娄婷叶,韩子明.肾病综合征脂蛋白脂酶和肝脂酶活性测定[J].实用儿科临床杂志,2005,20(5):409-410. 被引量:2
  • 10郭琴华,夏永辉.肾病综合征血脂检测及高血脂对肾脏、心血管的影响[J].实用儿科临床杂志,2005,20(5):420-422. 被引量:4

二级参考文献21

共引文献1558

同被引文献16

  • 1Papavasiliou EC,Gouva C,Siamopoulos KC,et al.PAF-acetylhydrolaseactivity in plasma of patients with chronic kidney disease.Effect of long-term therapy with erythropoietin[J].Nephrol Dial Transplant,2006,21(5):1270-1277.
  • 2Coppo R,Fonsato V,Balegno S,et al.Aberrantly glycosylated IgA1 in-duces mesangial cells to produce platelet-activating factor that mediatesnephrin loss in cultured podocytes[J].Kidney Int,2010,77(5):417-427.
  • 3McIntyre TM,Prescott SM,Stafforini DM.The emerging roles of PAFacetylhydrolase[J].J Lipid Res,2009,50(suppl):S255-S259.
  • 4Foulks JM,Marathe GK,Michetti N,et al.PAF-acetylhydrolase ex-pressed during megakaryocyte differentiation inactivates PAF-likelipids[J].Blood,2009,113(26):6699-6706.
  • 5Livnat I,Finkelshtein D,Ghosh I,et al,PAF-AH catalytic subunitsmodulate the Wnt pathway in developing GABAergic neurons[J].FrontCell Neurosci,2010,4:4.
  • 6Detopoulou P,Nomikos T,Fragopoulou E,et al.Lipoprotein-associa-ted phospholipase A2(Lp-PLA2)activity,platelet-activating factoracetylhydrolase(PAF-AH)in leukocytes and body composition inhealthy adults[J].Lipids Health Dis,2009,8:1-10.
  • 7Stafforini DM.Biology of platelet-activating factor acetylhydrolase(PAF-AH,lipoprotein associated phospholipase A2)[J].CardiovascDrugs Ther,2009,23(1):73-83.
  • 8Proudfoot JM,Barden AE,Loke WM.HDL is the major lipoprotein car-rier of plasma F2-isoprostanes[J].J Lipid Res,2009,50(4):716-722.
  • 9Seo HS,Nahm MH.Lipoprotein lipase and hydrofluoric acid deactivateboth bacterial lipoproteins and lipoteichoic acids,but platelet-activa-ting factor-acetylhydrolase degrades only lipoteichoic acids[J].ClinVaccine Immunol,2009,16(8):1187-1195.
  • 10Li S,Stuart L,Zhang Y,et al.Inter-individual variability of plasmaPAF-acetylhydrolase activity in ARDS patients and PAFAH genotype[J].J Clin Pharm Ther,2009,34(4):447-455.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部